# High blood pressure and protein in the urine on VEGF-pathway inhibitors: monitoring, treatment and when to pause the cancer medicine

Source: https://onco.cc/protocols/hypertension-and-proteinuria-on-vegf-pathway-inhibitors/  
OnCo record `hypertension-and-proteinuria-on-vegf-pathway-inhibitors` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Medicines that block VEGF often raise blood pressure, sometimes within days, and can put protein in the urine. Your team checks your blood pressure before you start, asks you to measure it at home, tests your urine, and treats high readings so treatment can go on. Contact the hospital straight away for a headache that does not get better, confusion, drowsiness, a fit or changes in eyesight.

## Summary

Hypertension is a class effect of VEGF-pathway inhibitors and the most reported adverse event on them; it occurs within hours or days, is dose dependent and is usually reversed when the drug stops (ESC 2022). Blood pressure is measured before the first dose and serially after it (ESMO 2020 [I, A]) and controlled before treatment starts (ESC 2022; the axitinib, lenvatinib, ramucirumab and fruquintinib labels each say so, the bevacizumab label does not). ESC 2022 recommends home measurement daily in the first cycle, after each dose increase and every 2 to 3 weeks thereafter (Class I, Level C), and measurement at every clinic visit (Class I, Level C). Labels set their own clinic schedules: lenvatinib after 1 week, then every 2 weeks for the first 2 months, then at least monthly; fruquintinib weekly for the first month, then at least monthly; ramucirumab every 2 weeks or more often; bevacizumab every 2 to 3 weeks.

The sources differ on when to treat. ESC 2022 sets a target below 140/90 mmHg during cancer therapy (Class I, Level C), allows below 130/80 mmHg if tolerated (Class IIb, Level C) and allows a 140 to 160 over 90 to 100 mmHg treatment threshold in selected asymptomatic people with metastatic cancer (Class IIb, Level C). IC-OS 2022 treats above 130/80 mmHg in people with cardiovascular disease, proteinuric kidney disease or diabetes and says the threshold can be extended to 140/90 mmHg in others. The AHA statement (2023) follows the general ACC/AHA rule, with a goal below 130/80 mmHg. ESC recommends an ACE inhibitor or ARB first (Class I, Level B), a dihydropyridine calcium channel blocker second (Class I, Level C), and the two together when systolic pressure is 160 mmHg or above and diastolic 100 mmHg or above (Class I, Level C); the AHA statement accepts any general first-line class and found insufficient evidence for any one strategy. Diltiazem and verapamil are not recommended by ESC (Class III, Level C), are to be used with caution in the AHA statement and are called typically contraindicated by ESMO, in each case because of drug interactions.

At 180 mmHg systolic or 110 mmHg diastolic, ESC and IC-OS say the cancer medicine should be deferred or temporarily withheld until blood pressure is below 160/100 mmHg (ESC Class I, Level C). Labels act earlier or on grade: axitinib is reduced above 150 mmHg systolic or 100 mmHg diastolic despite treatment and withheld above 160 mmHg systolic or 105 mmHg diastolic. Hypertensive crisis, hypertensive encephalopathy and posterior reversible encephalopathy syndrome end treatment with bevacizumab. The bevacizumab, lenvatinib and ramucirumab labels go from a urine dipstick of 2+ or more to a 24-hour collection; all five labels read withhold at 2 g or more of protein in 24 hours, and the bevacizumab, lenvatinib, ramucirumab and fruquintinib labels end treatment for nephrotic syndrome. When the cancer medicine stops, a drop in blood pressure must be anticipated and the blood pressure tablets reduced or interrupted (ESC). This page explains care; the treating team's own protocol and the product's current label come first.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: VEGF inhibitor hypertension; bevacizumab blood pressure; anti-angiogenic hypertension; TKI hypertension; proteinuria on bevacizumab; urine dipstick before bevacizumab; blood pressure on lenvatinib; blood pressure on axitinib; home blood pressure monitoring on cancer treatment; posterior reversible encephalopathy syndrome; PRES
- Tags: protocol; cardio-oncology; side-effect-management

## Connected records

- technologies: [Cardio-oncology](https://onco.cc/technologies/cardio-oncology/)
- protocols: [Atrial fibrillation, bleeding and high blood pressure on BTK inhibitors: assessment, monitoring and management](https://onco.cc/protocols/atrial-fibrillation-and-bleeding-on-btk-inhibitors/), [Bevacizumab and other anti-VEGF drugs around surgery: pausing before and restarting after](https://onco.cc/protocols/anti-vegf-drugs-around-surgery/), [Drug, herbal and food interaction review for anticancer treatment](https://onco.cc/protocols/anticancer-drug-interaction-review/), [Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment](https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/), [QT prolongation on cancer medicines: ECG and blood salt monitoring, and when to pause or stop](https://onco.cc/protocols/qt-prolongation-monitoring-on-anticancer-drugs/), [Underactive thyroid on VEGFR-targeted tyrosine kinase inhibitors: thyroid tests and levothyroxine](https://onco.cc/protocols/hypothyroidism-on-tyrosine-kinase-inhibitors/)
- key papers: [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://onco.cc/key-papers/paper-lyon-eur-heart-j/)
- fronts: [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- targets: [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- drugs: [Axitinib](https://onco.cc/drugs/axitinib/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Pazopanib](https://onco.cc/drugs/pazopanib/), [Ponatinib](https://onco.cc/drugs/ponatinib/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/), [Regorafenib](https://onco.cc/drugs/regorafenib/), [Sorafenib](https://onco.cc/drugs/sorafenib/), [Sunitinib](https://onco.cc/drugs/sunitinib/), [Tivozanib](https://onco.cc/drugs/tivozanib/), [Vandetanib](https://onco.cc/drugs/vandetanib/)
- institutions: [European Society for Medical Oncology (ESMO)](https://onco.cc/institutions/esmo/)
- terms: [Angiogenesis](https://onco.cc/terms/angiogenesis/), [Cardiotoxicity (LVEF decline, cardiomyopathy)](https://onco.cc/terms/cardiotoxicity/)

---
JSON: https://onco.cc/api/v1/entities/hypertension-and-proteinuria-on-vegf-pathway-inhibitors.json